Veru Inc (VERU)

[Biobonic]

Today's news Plenty of run left in this...

Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020
MIAMI , Jan. 21, 2020 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), The Prostate Cancer Company, an oncology and urology biopharmaceutical company developing novel medicines for the management of prostate cancer, today announced that two of its abstracts have been accepted for presentation at the upcoming 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium to be held February 13-15, 2020, at the Moscone West Building in San Francisco, California.

One of the presentations will provide preclinical data on VERU-100, the Company’s novel, proprietary peptide formulation for androgen deprivation therapy (ADT) developed with multiple potential beneficial clinical attributes to address the shortfalls of current FDA-approved ADT formulations for the treatment of advanced prostate cancer. VERU-100 is a long-acting gonadotropin-releasing hormone (GnRH) antagonist designed to be administered as a small volume subcutaneous 3-month depot injection without a loading dose.

The other presentation reports findings from a recent study in a contemporary cohort of men on ADT to determine the magnitude of the impact that hot flashes are having on these men and their disease management. The Company has a novel, proprietary, oral, nonsteroidal, estrogen receptor agonist, Zuclomiphene citrate, that is currently being evaluated in a Phase 2 clinical study to treat hot flashes, one of the most common and impactful side effects caused by ADT.